To main content

Cardiac Alarmins as Residual Risk Markers of Atherosclerosis under Hypolipidemic Therapy

Abstract

Increased levels of low-density lipoproteins are the main risk factor in the initiation and progression of atherosclerosis. Although statin treatment can effectively lower these levels, there is still a residual risk of cardiovascular events. We hypothesize that a specific panel of stress-sensing molecules (alarmins) could indicate the persistence of silent atherosclerosis residual risk. New Zealand White rabbits were divided into: control group (C), a group that received a high-fat diet for twelve weeks (Au), and a treated hyperlipidemic group with a lipid diet for eight weeks followed by a standard diet and hypolipidemic treatment (atorvastatin and PCSK9 siRNA-inhibitor) for four weeks (Asi). Mass spectrometry experiments of left ventricle lysates were complemented by immunologic and genomic studies to corroborate the data. The hyperlipidemic diet determined a general alarmin up-regulation tendency over the C group. A significant spectral abundance increase was measured for specific heat shock proteins, S100 family members, HMGB1, and Annexin A1. The hypolipidemic treatment demonstrated a reversed regulation trend with non-significant spectral alteration over the C group for some of the identified alarmins. Our study highlights the discriminating potential of alarmins in hyperlipidemia or following hypolipidemic treatment. Data are available via ProteomeXchange with identifier PXD035692.
Read the publication

Category

Academic article

Language

English

Author(s)

  • Viorel I. Suica
  • Elena Uyy
  • Luminita Ivan
  • Raluca M. Boteanu
  • Aurel Cerveanu-Hogas
  • Rune Hansen
  • Felicia Antohe

Affiliation

  • SINTEF Digital / Health Research
  • Romania
  • Norwegian University of Science and Technology

Year

2022

Published in

International Journal of Molecular Sciences

ISSN

1661-6596

Volume

23

Issue

19

View this publication at Norwegian Research Information Repository